Search for:

In brief

With a decision published in the EU Official Journal on 31 July 2021, the European Commission confirmed that the EU Portal and Database have achieved full functionality. This implies that Regulation (EU) No. 536/2014 on clinical trials will be applicable as of 31 January 2022, in accordance with the provisions of Article 99 of the same Regulation.


In depth

The EU Portal and Database represent the key components of the Clinical Trial Information System (CTIS) introduced by Regulation (EU) No. 536/2014, which will be the single entry point for the submission of data and information relating to clinical trials in the EU and in the European Economic Area (EEA).

Moreover, through the CTIS, sponsors will no longer be required to submit separate applications in each EEA country where the trial is conducted, but will be able to apply for a clinical trial authorization in more than one country by submitting one single application. The CTIS will also facilitate the recruitment of trial participants by allowing sponsors and investigators to easily extend trials to other EEA countries and achieve better results through knowledge sharing.

Author

Roberto Cursano has been a lawyer in Baker McKenzie since September 2007. He focuses on healthcare law and compliance, and assists in tender procedures, the negotiation of public contracts and litigation before administrative courts. Mr. Cursano is a former administrative officer in the Italian Ministry of Health and helps clients work closely with the Italian Public Administration. He is admitted to the bar before the Italian Supreme Court and the Council of State. As well as training and tutoring in the master’s degree program on clinical trials of pharmaceutical products at the University of Rome Sapienza, Mr. Cursano regularly publishes articles and scientific contributions. He also frequently hosts and participates in seminars and presentations on pharmaceutical and administrative law matters.

Author

Riccardo Ovidi is an Associate in Baker McKenzie Rome office.

Write A Comment